UBS Group’s Turnstone Biologics TSBX Stock Holding History

UBS Group’s Portfolio TSBX Stock Details TSBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-71	Closed	-$25	–	10939
2025 Q2	$25	Hold	71	–	–	﹤0.01%	10107
2025 Q1	$29	Hold	71	–	–	﹤0.01%	10058
2024 Q4	$35	Sell	71 -10,572	-99%	-$5.22K	﹤0.01%	9738
2024 Q3	$5.93K	Buy	10,643 +9,092	+586%	+$14K	﹤0.01%	8014
2024 Q2	$4.06K	Sell	1,551 -17,506	-92%	-$50K	﹤0.01%	8134
2024 Q1	$49.9K	Buy	19,057 +11,886	+166%	+$34K	﹤0.01%	6505
2023 Q4	$18.3K	Buy	7,171 +5,800	+423%	+$15.1K	﹤0.01%	7159
2023 Q3	$5.4K	Buy	+1,371	New	+$12.2K	﹤0.01%	7373

UBS Group's TSBX Position: Q3 2025 in Review

UBS Group sold out of Turnstone Biologics (TSBX) in Q3 2025, closing a stake of 71 shares — an estimated $25 sold.

UBS Group first reported a position in TSBX in Q3 2023 and held it in 8 quarters. The position peaked at $49.9K in Q1 2024. 1 fund tracked by Wall St. Rank holds TSBX as of Q3 2025.

UBS Group reported no remaining Turnstone Biologics position as of Q3 2025 after selling out during the quarter.
UBS Group sold 71 Turnstone Biologics shares in Q3 2025, an estimated $25.
UBS Group first reported a position in Turnstone Biologics in Q3 2023 and held it in 8 quarters.
UBS Group's Turnstone Biologics position peaked at $49.9K in Q1 2024.
1 fund tracked by Wall St. Rank held Turnstone Biologics as of Q3 2025.

Based on UBS Group's 13F filing for Q3 2025, filed 13 Nov 2025.